Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 6.46B 5.62B 5.23B 4.8B 9.06B 617B 9.2B 61.62B 24.18B 307B 24.26B 23.73B 1,030B P/E 2026 *
-6.78x
P/E 2027 * -162x
Enterprise Value 6.5B 5.65B 5.26B 4.83B 9.11B 620B 9.25B 61.95B 24.31B 309B 24.4B 23.86B 1,035B EV / Sales 2026 *
9.62x
EV / Sales 2027 * 7.85x
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
1 day-5.90%
1 week-6.26%
1 month-9.50%
3 months+8.88%
6 months+2.64%
Current year+34.13%
1 week 105.7
Extreme 105.7
116.39
1 month 105.7
Extreme 105.7
130
Current year 73.82
Extreme 73.82
130
1 year 50.25
Extreme 50.25
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Fiscal year

Founder

60,000 0.0984%
7/6/26 Sell

Chief Financial Officer

-5,000 0.0082%
7/1/26 Sell

Controller/Auditor

-2,721 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
-5.90%-6.26%+105.01%+311.30% 6.46B
-0.53%-3.95%+55.23%+152.74% 1,024B
+0.21%-2.68%+55.61%+53.02% 618B
-2.51%-3.25%+32.76%+67.76% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.14%-0.24%+34.41%+39.01% 297B
-0.69%-0.30%+11.55%+12.93% 264B
-7.37%-4.40%-2.54%-43.87% 209B
-0.64%+2.43%+30.52%+64.49% 208B
-0.82%+0.70%+15.96%+71.01% 162B
Average -1.83%-1.70%+37.60%+75.91% 358.02B
Weighted average by Cap. -1.00%-1.94%+39.36%+73.38%

Financials

2026 *2027 *
Net sales 675M 587M 546M 502M 947M 64.46B 962M 6.44B 2.53B 32.09B 2.54B 2.48B 108B 815M 709M 660M 606M 1.14B 77.81B 1.16B 7.77B 3.05B 38.74B 3.06B 2.99B 130B
Net income -910M -791M -736M -676M -1.28B -86.84B -1.3B -8.68B -3.41B -43.23B -3.42B -3.34B -145B -1.62M -1.41M -1.31M -1.21M -2.28M -155M -2.31M -15.47M -6.07M -77.09M -6.09M -5.96M -258M
Net Debt 34.69M 30.15M 28.07M 25.77M 48.66M 3.31B 49.42M 331M 130M 1.65B 130M 127M 5.53B -61.06M -53.08M -49.41M -45.36M -85.66M -5.83B -86.99M -582M -229M -2.9B -229M -224M -9.73B
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
418
Date Price Change Volume
26-07-31 US$105.95 -5.90% 578,735
26-07-30 US$112.59 +4.67% 575,875
26-07-29 US$107.57 -4.15% 682,487
26-07-28 US$112.23 -1.73% 437,935
26-07-27 US$114.20 +1.04% 431,343
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
105.95USD
Average target price
146.50USD
Spread / Average Target
+38.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIRM Stock